AOD-14 Evidence Guide
Evidence for AOD-14 is too preliminary to support a research protocol with confidence. This is an early-stage compound with minimal published data and no clinical trials. There is no basis for selecting it over better-characterized healing peptides in this library.
Our Take
Evidence for AOD-14 is too preliminary to support a research protocol with confidence. This is an early-stage compound with minimal published data and no clinical trials. There is no basis for selecting it over better-characterized healing peptides in this library.
- Best for
- No validated application at this stage
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Wound Closure Acceleration: Level D, mostly non-human evidence - Li et al. (2015, Peptides) reported AOD-9604 fragment-derived peptides accelerated keratinocyte migration by 35-40% in in vitro scratch assays at 100 nM; one preliminary murine excisional wound study showed ~20% faster wound closure at day 7 vs. vehicle, though peer-reviewed replication is lacking.
- Tissue Regeneration: Level D, mostly non-human evidence - Early preclinical data indicates possible enhancement of tissue regeneration quality, with improved collagen organization and reduced scar formation.
Side Effects and Warnings
- No clinical safety data available
- In vitro studies have not identified significant cytotoxicity
- Theoretical risk of excessive tissue growth at high concentrations
- Extremely early stage of research
- No clinical trials have been conducted
- Safety profile is entirely unknown in humans
- Limited published literature available
Research Dosage References
- <strong>Topical</strong> - 50-200 mcg/mL - Daily - Experimental dosing in research settings only. No clinical dosing established.
Mechanism of Action
AOD-14 is proposed to promote tissue repair through: 1. Growth factor mimicry: Mimics certain growth factor signaling cascades involved in the proliferative phase of wound healing. 2. Matrix metalloproteinase regulation: Modulates MMP-2 and MMP-9 activity to balance extracellular matrix degradation and deposition during tissue remodeling. 3. Cell migration promotion: Enhances epithelial and endothelial cell migration toward wound sites through integrin-mediated signaling. 4. Anti-inflammatory effects: Reduces excessive inflammatory response that impedes normal wound healing progression.
Legal Status
AOD-14 is a research compound in early stages of investigation. Not approved or available for clinical use. Not scheduled as a controlled substance. Available only through specialized research suppliers.
Primary Sources
- Synthetic peptides for wound healing: current status and future directions. J Pept Sci, 2018.
- Novel peptide-based approaches to tissue repair and regeneration. Adv Wound Care, 2012.